Medicare Under Fire For Not Covering Most Claims For New Alzheimer’s Drug, Aduhelm
by Richard Kuehn on 03/03/22
Drugmakers and patient advocacy groups are pushing back against a federal proposal to cut off most Medicare payments for a new drug
from Biogen Inc. to treat Alzheimer’s, called Aduhelm. The Centers for Medicare and Medicaid
Services last month proposed to limit coverage of the drug to patients enrolled
in clinical trials which are sanctioned by the agency. The proposal would apply to similar drugs
still in development and not yet approved that work by reducing amyloid protein
in the brain. The high cost of the drug
and questions over its efficacy are behind the decision of the Centers for
Medicare and Medicaid Services.
Comments (0)
